The Fas/Fas ligand (FasL) system is one apoptotic pathway through which malignant tumors can evade immune surveillance. While FasL is expressed in malignant tumors, Fas is conversely downregulated to escape host immune attack, resulting in tumor invasion. The aim of the current study was to find out further clinicopathological significance of FasL expression in carcinoma of the colon and rectum. FasL expression was investigated using immunohistochemical staining in 143 consecutive patients with primary colorectal carcinomas. Seventy-nine carcinomas (55.2%) expressed FasL. The incidence of lymph node and distant metastases in carcinomas expressing FasL was significantly higher than in carcinomas that did not express FasL (p = 0.031 and p = 0.0003, respectively). Although univariate analysis showed that survival in patients with carcinomas expressing FasL was significantly poorer than that in patients with carcinomas without FasL expression (p = 0.001), only Dukes’ stage was an independent prognosticator by multivariate analysis. FasL expression was found to be correlated with lymph node involvement and distant metastases in colorectal carcinoma.

1.
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233–243.
2.
Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709–10715.
3.
Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S: Human Fas ligand: Gene structure, chromosomal location and species specificity. Int Immunol 1994;6:1567–1574.
4.
Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169–1178.
5.
Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630–632.
6.
Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189–1192.
7.
Nagata S, Golstein P: The Fas death factor. Science 1995;267:1449–1456.
8.
Morimoto Y, Hizuta A, Ding EX, Ishii T, Hongo T, Fujiwara T, Iwagaki H, Tanaka N: Functional expression of Fas and Fas ligand on human intestinal intraepithelial lymphocytes. Clin Exp Immunol 1999;116:84–89.
9.
Robbins PF, Kawakami Y: Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628–636.
10.
Sheu BC, Lin RH, Ho HN, Huang SC: Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum Immunol 1997;56:39–48.
11.
Jaffe ML, Arai H, Nabel GJ: Mechanisms of tumor-induced immunosuppression: Evidence for contact-dependent T cell suppression by monocytes. Mol Med 1996;2:692–701.
12.
Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH: Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999;154:693–703.
13.
Rayman P, Uzzo RG, Kolenko V, Bloom T, Cathcart MK, Molto L, Novick AC, Bukowski RM, Hamilton T, Finke JH: Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape. Cancer J Sci Am 2000;6:S81–S87.
14.
Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S, Caignard A: Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res 2001;61:3240–3244.
15.
O’Connell J, O’Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075–1082.
16.
Zietz C, Rumpler U, Sturzl M, Lohrs U: Inverse relation of fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: Indications of apoptotic tumor counterattack. Am J Pathol 2001;159:963–970.
17.
Nagashima H, Mori M, Sadanaga N, Mashino K, Yoshikawa Y, Sugimachi K: Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 2001;18:1157–1162.
18.
Younes M, Schwartz MR, Ertan A, Finnie D, Younes A: Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 2000;88:524–528.
19.
Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H, Nakamori S, Dono K, Sakon M, Nakamura M, Tsujimoto M, Nakahara M, Nakao K, Yokosaki Y, Matsuura N: The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000;82:1211–1217.
20.
Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K: Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000;82:1446–1452.
21.
Koomagi R, Volm M: Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999;84:239–243.
22.
Japanese Research Society for Cancer of the Colon and Rectum: General rules for clinical and pathologic studies on cancer of the colon, rectum and anus. Jpn J Surg 1983;13:557–573.
23.
O’Connell J, Bennett MW, O’Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F: Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998;186:240–246.
24.
Younes M, Schwartz MR, Finnie D, Younes A: Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett’s metaplasia of the esophagus. Hum Pathol 1999;30:1309–1313.
25.
Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, Pieri F, Fraternali-Orcioni G, Pileri SA: The EnVision++ system: A new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998;51:506–511.
26.
Kammerer U, Kapp M, Gassel AM, Richter T, Tank C, Dietl J, Ruck P: A new rapid immunohistochemical staining technique using the EnVision antibody complex. J Histochem Cytochem 2001;49:623–630.
27.
Shimoyama M, Kanda T, Liu L, Koyama Y, Suda T, Sakai Y, Hatakeyama K: Expression of Fas ligand is an early event in colorectal carcinogenesis. J Surg Oncol 2001;76:63–68.
28.
Dukes CE: The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323–332.
29.
Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T: Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000;6:3560–3564.
30.
Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94:6420–6425.
31.
Bennett MW, O’Connell J, Houston A, Kelly J, O’Sullivan GC, Collins JK, Shanahan F: Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol 2001;54:598–604.
32.
Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C: FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999;79:1262–1269.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.